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Identifying colorectal cancer caused by biallelic
MUTYH pathogenic variants using tumor
mutational signatures
Peter Georgeson 1,2, Tabitha A. Harrison3, Bernard J. Pope 1,2,4, Syed H. Zaidi5, Conghui Qu3,
Robert S. Steinfelder3, Yi Lin3, Jihoon E. Joo1,2, Khalid Mahmood1,2,4, Mark Clendenning1,2, Romy Walker1,2,
Efrat L. Amitay 6, Sonja I. Berndt7, Hermann Brenner6,8,9, Peter T. Campbell10, Yin Cao11,12,13,
Andrew T. Chan 14,15,16,17,18,19, Jenny Chang-Claude 20,21, Kimberly F. Doheny 22, David A. Drew14,15,
Jane C. Figueiredo23,24, Amy J. French25, Steven Gallinger5,26, Marios Giannakis 17,27,28,
Graham G. Giles 29,30,31, Andrea Gsur 32, Marc J. Gunter33, Michael Hoffmeister 6, Li Hsu3,34,
Wen-Yi Huang 7, Paul Limburg35, JoAnn E. Manson18,28, Victor Moreno 36,37,38,39, Rami Nassir40,
Jonathan A. Nowak41, Mireia Obón-Santacana36,37, Shuji Ogino 17,18,41,42, Amanda I. Phipps3,43,
John D. Potter 3,44, Robert E. Schoen 45, Wei Sun 3, Amanda E. Toland 46, Quang M. Trinh 5,
Tomotaka Ugai18,41, Finlay A. Macrae47,48,49, Christophe Rosty1,2,50,51, Thomas J. Hudson 5,
Mark A. Jenkins 2,30, Stephen N. Thibodeau25, Ingrid M. Winship49,52, Ulrike Peters 3,43,53 &
Daniel D. Buchanan 1,2,49,53 ✉

Carriers of germline biallelic pathogenic variants in the MUTYH gene have a high risk of
colorectal cancer. We test 5649 colorectal cancers to evaluate the discriminatory potential of
a tumor mutational signature speciﬁc to MUTYH for identifying biallelic carriers and classifying variants of uncertain clinical signiﬁcance (VUS). Using a tumor and matched germline
targeted multi-gene panel approach, our classiﬁer identiﬁes all biallelic MUTYH carriers and
all known non-carriers in an independent test set of 3019 colorectal cancers (accuracy =
100% (95% conﬁdence interval 99.87–100%)). All monoallelic MUTYH carriers are classiﬁed with the non-MUTYH carriers. The classiﬁer provides evidence for a pathogenic classiﬁcation for two VUS and a benign classiﬁcation for ﬁve VUS. Somatic hotspot mutations
KRAS p.G12C and PIK3CA p.Q546K are associated with colorectal cancers from biallelic
MUTYH carriers compared with non-carriers (p = 2 × 10−23 and p = 6 × 10−11, respectively).
Here, we demonstrate the potential application of mutational signatures to tumor sequencing
workﬂows to improve the identiﬁcation of biallelic MUTYH carriers.

A full list of author afﬁliations appears at the end of the paper.
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enome-wide tumor proﬁling and associated computational approaches can provide a historical record of the
mutational processes, both endogenous and exogenous,
that were active during tumor initiation and progression, providing a tumor mutational signature (TMS) proﬁle1,2. Several of
these TMSs have been mechanistically shown to result from
genetic defects related to homologous recombination repair
deﬁciency3, DNA mismatch repair deﬁciency4, and base excision
repair deﬁciency5,6, including in colorectal cancer (CRC)7,8.
Therefore, TMSs can represent a functional manifestation of
speciﬁc alterations in DNA repair pathways, with the potential
application for not only identifying tumors caused by inherited
defects in DNA repair genes but also providing functional evidence to support variant classiﬁcation approaches in these DNA
repair genes. The increasing application of tumor sequencing to
identify targets for personalized therapy provides an opportunity
to implement TMS analysis to gain additional clinically relevant
knowledge on hereditary susceptibility earlier.
Identifying pathogenic variants in CRC and polyposis susceptibility genes has important implications for preventing subsequent primary cancers in the carrier6,9,10 and for the prevention
of CRC in relatives through targeted screening approaches such
as colonoscopy with polypectomy. The most common recessively
inherited CRC and polyposis susceptibility genes include
MUTYH11,12, and NTHL16,13. Germline carriers of biallelic
pathogenic variants in the MUTYH gene are almost certain to
develop CRC, although monoallelic carriers of a MUTYH
pathogenic variant may have only a small increased risk of
CRC14. Current indications for germline testing for MUTYH
include >20 colonic adenomas, although the phenotype has been
described as variable where some biallelic MUTYH carriers
develop CRC without the associated polyposis, suggesting biallelic
MUTYH carriers may be missed with this current approach15.
Unlike Lynch syndrome, where DNA mismatch repair immunohistochemistry is used on tumor samples for triaging patients
to identify pathogenic variant carriers, no tumor-based biomarkers or testing approaches are currently used in diagnostic
pathology to triage people for identifying germline biallelic
MUTYH carriers.
A TMS proﬁle characteristic of biallelic inactivation of
MUTYH has been described in CRC5,16 and in other cancer
types17. In previous work we evaluated all the existing speciﬁc
single base substitution (SBS) and indel (ID) TMS using wholeexome sequencing of CRCs, demonstrating that the SBS TMSs,
SBS18, and SBS36, when combined were the dominant TMSs in
CRCs from biallelic MUTYH pathogenic variant carriers7. To
support the application of SBS18 and SBS36 in the clinical setting,
further evidence related to the accuracy of this approach is needed, particularly when applied to targeted panel sequencing data.
Furthermore, our previous work generated the hypothesis that a
combined SBS18 and SBS36 TMS could be applied to support the
classiﬁcation of germline MUTYH variants of uncertain clinical
signiﬁcance (VUS).
In this study, we: (1) evaluate the performance of SBS18 and
SBS36 TMSs to identify germline biallelic pathogenic variant
carriers and classify variants in the MUTYH gene in a large series
of CRCs from the Genetic Epidemiology of Colorectal cancer
Consortium (GECCO) tested with custom-designed targeted
tumor sequencing assays, and (2) identify somatic mutation
associations with biallelic MUTYH carriers within the somatic
mutation landscape of CRCs.
Results
Distribution and classiﬁcations of CRCs across the study. The
germline and somatic variants identiﬁed in MUTYH from all
2

5649 CRCs assessed in this study are summarized in Supplementary Fig. 1. Each tumor was categorized into one of ﬁve
groups based on carriership of MUTYH variants and their classiﬁcation as pathogenic, benign, or VUS (further deﬁned in
Supplementary Table 1): (1) MUTYH positives: tumors in people
found to be germline carriers of two pathogenic variants (compound heterozygotes) or a homozygous pathogenic variant in
MUTYH; (2) MUTYH monoallelics: tumors with only one
germline heterozygous pathogenic variant in MUTYH and no
other germline potential pathogenic variants; (3) MUTYH negatives: tumors with no germline or somatic pathogenic or potential
pathogenic variants identiﬁed in MUTYH; (4) potential MUTYH
biallelics: tumors in people homozygous for a germline potentially
pathogenic variant or with two variants classiﬁed as either
pathogenic or potentially pathogenic, but not two pathogenic
variants; and (5) MUTYH uncertain: tumors in people with only
one heterozygous potentially pathogenic or heterozygous somatic
pathogenic variant.
The tumors assessed were derived from 18 studies (Supplementary Table 2). The study design and distribution of tumors
into training, validation, and test sets are summarized in Fig. 1.
The demographic and clinic-pathological characteristics of the
5649 CRCs by training, validation, and test sets, by tumor
MUTYH classiﬁcation, and by recruiting study are shown in
Supplementary Tables 2–5, respectively.
Pathogenic variants in MUTYH. The pathogenic variants and
clinicopathological characteristics of each of the 19 CRCs from
biallelic MUTYH carriers are detailed in Supplementary Table 6.
No MUTYH positive tumor showed microsatellite instability
(MSI) according to MSIseq predictions. There were 79 monoallelic MUTYH pathogenic variant carriers and 17 potential
MUTYH biallelics identiﬁed (Supplementary Table 7). Figure 2
summarizes the overall TMS proﬁles of the 19 MUTYH positive
CRCs and the 17 CRCs from potential MUTYH biallelics
(expanded to include all CRCs from MUTYH monoallelic carriers
in Supplementary Fig. 2). Supplementary Fig. 3 and Supplementary Table 8 summarize the aggregated contexts and mutational signatures observed for each tumor class, respectively.
SBS18/36 TMS threshold for identifying CRCs from MUTYH
positives and its accuracy for discriminating MUTYH positives
from MUTYH negatives. From the training set of 102 CRCs,
including 8 MUTYH positive CRCs, we calculated the likelihood
of biallelic MUTYH base excision repair deﬁciency TMS to be
95% when the sum of SBS18 and SBS36 exceeded 51% (range
from 60.2 to 93.4%; Supplementary Table 9; Supplementary
Fig. 4). We then assessed the accuracy of this baseline SBS18/36
classiﬁer on the validation set of 2528 CRCs. All 6 MUTYH
positives were correctly identiﬁed using the 51% SBS18/36
threshold, with no false negatives (Fig. 3a). Of the 2424 MUTYH
negative CRCs, 45 were incorrectly classiﬁed as MUTYH positive
and thus considered false positives. Therefore, the baseline classiﬁer achieved 98.1% accuracy (95% conﬁdence interval
97.5–98.6%), with 100% sensitivity (54.1–100%) and 98.1% speciﬁcity (97.5–98.6%) when applied to the validation set.
The number of somatic mutations and degree of TMS reconstruction error are associated with false positive SBS18/36
TMS. We conﬁrmed the absence of pathogenic variants in the 45
false positives by examining the sequencing data for any pathogenic variants that may have been overlooked by the variant
calling pipeline. To determine features that could improve classiﬁcation accuracy, we assessed each tumor’s somatic mutation
count and TMS reconstruction error. The MUTYH positive CRCs
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Training set (n=102)

Test set (n=3,019)

Validation set (n=2,528)

WES downsampled to 1.34Mb panel

GECCO CIDR: 1.96Mb panel

GECCO OICR: 1.34Mb panel

MUTYH Positives (8)

MUTYH Positives (6)

MUTYH Positives (5)

MUTYH Negatives (92)

MUTYH Negatives (2,424)

MUTYH Negatives (2,848)

Establishment of SBS18/SBS36
threshold for identifying biallelic
MUTYH CRCs

Evaluate TMS
for biallelic
MUTYH CRCs

Refinement of classifier for
biallelic MUTYH CRCs

Assess classifier
for biallelic
MUTYH CRCs

Classifier Performance
All positives correctly classified
All negatives correctly classiied
Accuracy 100% (CI 99.87-100%)

Apply to tumors with
unknown status
Assess monoallelic
impact on TMS

Uncertain (n=170)
1x germline VUS (108)
1x somatic VUS/PV (56)
1x germline insilico VUS (6)

99.4% (169 of 170) classified negative
1 tumor with germline POLD1 PV
showed high SBS18/SBS36

Potential Biallelics (n=17)
1x germline PV, 1+ VUS (9)
1x homozygous VUS (3)
2+ VUS (5)

17.6% (3 of 17) classified positive
2 VUSs reclassified likely pathogenic
5 VUSs reclassified likely benign

Monoallelic Carriers (n=79)
Training set MUTYH PV carriers(2)
Validation set MUTYH PV carriers (32)
Test set MUTYH PV Carriers (45)

100% classified negative
Requirement of biallelic MUTYH
inactivation to observe TMS
Somatic second hit is rare

Fig. 1 Overview of the analysis steps and groups of CRC tumor sequencing data included in the study, totaling 5649 CRCs. The SBS18/SBS36 TMS
threshold was established using 102 CRCs down-sampled from whole-exome sequenced (WES) to intersect with the 1.34 Mb capture used to sequence
the CRC tumors in the validation set. The 2528 CRCs sequenced with 1.34 Mb capture as part of the validation set were used to reﬁne the SBS18/SBS36
classiﬁer by including the somatic mutation count and TMS reconstruction error. The accuracy of the reﬁned classiﬁer was assessed using 3019 CRC
tumors sequenced with a 1.96 Mb capture as part of the test set. The reﬁned classiﬁer was subsequently applied to 79 CRCs from monoallelic MUTYH
pathogenic variant carriers, and CRCs deﬁned as potential MUTYH biallelics and MUTYH uncertain status to determine its utility in variant classiﬁcation. CI
conﬁdence interval, CIDR Center for Inherited Disease Research, CRC colorectal cancer, GECCO Genetic Epidemiology of Colorectal cancer Consortium,
Mb megabase, OICR Ontario Institute of Cancer Research, PV pathogenic variant, SBS single bases substitution, TMS tumor mutational signature, VUS
variant of uncertain clinical signiﬁcance.

from the training set (n = 8) and from the validation set (n = 6)
exhibited a somatic mutation count ranging from 9 to 32
(mean ± SD 20.8 ± 7.8). In contrast, the 45 false positive CRCs
from the validation set exhibited signiﬁcantly lower somatic
mutation counts, ranging from 1 to 12 (mean ± SD of 5.1 ± 2.6;
p = 8 × 10−17, t-test). The 14 MUTYH positives from the training
and validation sets exhibited reconstruction error ranging from
8.9 to 32.7% (mean ± SD 19.8 ± 8.3%), whereas the 45 false
positive CRCs showed signiﬁcantly higher reconstruction error
ranging from 20.6 to 73.1% (mean ± SD 54.0 ± 11.5%;
p = 1 × 10−14, t-test). By considering somatic mutation count and
reconstruction error, the 45 false positives could be differentiated
from the 14 MUTYH positives, evidenced by 43 of 45 CRCs
(96%) having a reconstruction error >39%, and 40 of 45 (89%)
having <9 somatic mutations (Figs. 3a–c, 4a, b). Combining these
two constraints eliminated all false positives while still detecting
all 14 MUTYH positives, providing an optimized MUTYH TMS
classiﬁer.
Evaluating the optimized MUTYH TMS classiﬁer on an independent test set of CRCs. We applied this optimized classiﬁer,
comprising SBS18 + SBS36 > 51%, reconstruction error <39%,
and somatic mutation count ≥9, to the independent test set
(n = 3019), with the somatic mutation counts adjusted for the
differing panel sizes. All ﬁve MUTYH positives and all 2848
MUTYH negatives were correctly identiﬁed. This corresponds to
100% accuracy (95% CI 99.87–100%), sensitivity (47.8–100%),

and speciﬁcity (99.87–100%) (Fig. 1), demonstrating the classiﬁer’s likely generalizability to independent data.
Classifying CRCs from MUTYH monoallelics and potential
MUTYH biallelics. The SBS18/36 TMS was signiﬁcantly higher in
biallelic MUTYH carrier CRCs compared with both non-MUTYH
carrier CRCs (p = 3 × 10−112, t-test) and monoallelic MUTYH
pathogenic variant carrier CRCs (p = 5 × 10−29, t-test). When
applying our optimized classiﬁer, none of the 79 MUTYH
monoallelics were classiﬁed as positive (Fig. 4a, b), demonstrating
that monoallelic inactivation of MUTYH is insufﬁcient to observe
the SBS18/36 TMS in CRCs. To investigate somatic inactivation
of the wildtype allele in the MUTYH monoallelics, we assessed
loss of heterozygosity (LOH) as a potential second somatic event.
Evidence of LOH across MUTYH was observed in 4% (224/5649)
of CRCs in this study, but these tumors did not show signiﬁcantly
elevated SBS18/36. The 224 tumors with LOH spanning MUTYH
were supported by 8.2 ± 7.2 mutations (mean ± sd) across the
entire LOH region, with 1.8 ± 0.9 mutations within 100,000 bases
of MUTYH. Public data suggests LOH does not commonly affect
MUTYH: 0/60 Pan-Cancer Analysis of Whole Genomes
(PCAWG) CRCs and 69/583 (12%) of The Cancer Genome Atlas
(TCGA) CRCs showed evidence of copy number loss across
MUTYH. Structural variants are similarly rare18. Four of the 79
(5%) MUTYH monoallelics exhibited LOH but none were classiﬁed as positive based on the classiﬁer. Additionally, 61 tumors
harbored pathogenic or potentially pathogenic somatic mutations
in MUTYH across the entire cohort (1.1%), but no pathogenic
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c.933+3A>C
c.1141G>T
c.1147del
c.1187 G>A
c.1214C>T
c.1227_1228dupGG
c.1276C>T
c.1286G>T
c.1420C>T
c.1431G>C
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c.1596C>A

SBS40
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c.53C>T
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SBS37
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Fig. 2 Observed tumor mutational signature proﬁles for 19 CRCs from germline biallelic MUTYH pathogenic variant carriers, and 17 CRCs carrying
more than one MUTYH pathogenic or potentially pathogenic variant but not two pathogenic variants (potential biallelic). All the CRCs from the
germline biallelic MUTYH PV carriers exhibit dominant SBS18 and/or SBS36 tumor mutational signature. Source data are provided as a Source Data ﬁle.

somatic mutation in MUTYH was observed in any of the
monoallelic CRCs, suggesting a second somatic event is a rare
event in MUTYH monoallelic carriers. We did not observe any
statistically signiﬁcant association between SBS18/36 and tumor
stage in the monoallelic or biallelic carriers (Supplementary
Table 10 and Supplementary Fig. 5).
Given this differential in biallelic and monoallelic MUTYH
carriers, we applied the optimized classiﬁer to 17 potential
MUTYH biallelic CRCs carrying more than one variant (germline
or somatic) classiﬁed as either pathogenic or VUS to determine if
the SBS18/36 TMS could provide functional evidence for biallelic
inactivation and, therefore, support variant classiﬁcation
(Table 1). For two VUSs, p.G381W and c.577-5A>G, the TMSs
provide support for pathogenicity (Table 1). Neither variant has
been seen in gnomAD and have inconclusive computational
predictions by REVEL and CADD, but the high observed TMS, in
conjunction with acceptable reconstruction error, somatic mutation count, and no evidence for LOH, adds support for
pathogenicity. Similarly, the high TMS observed in tumor
C5024 suggests that one of these VUSs c.933+3A>C or
p.A489T is likely to be pathogenic. For ﬁve VUSs, p.R426C,
p.S304R, p.R274Q, p.R309C, and p.T477T, our classiﬁer adds
evidence suggesting that these variants are likely benign. In
particular, p.R309C was homozygous in two independent tumors
that the classiﬁer predicted to be MUTYH negative. Participant
O1569 carried the germline monoallelic pathogenic variant
c.1187G>A p.G396D and a second germline variant c.821G>A
p.R274Q classiﬁed as a VUS by ClinVar (REVEL 0.826; CADD
33). Previous studies suggest that c.R274Q mutant MUTYH has
partial activity compared to wild-type protein19,20. In this tumor,
ten somatic mutations were detected with high reconstruction
error (45.8%) and SBS18/36 TMS of 24.9%—which suggests <1%
4

likelihood of the tumor being related to biallelic MUTYH
inactivation (Supplementary Table 9). This adds evidence that
c.821G>A p.R274Q is likely benign.
Of the 170 tumors in MUTYH uncertain group (Supplementary
Table 7), 169 were classiﬁed as MUTYH negative by the classiﬁer.
The single positive tumor exhibited high mutational burden (93.7
mutations/megabase (Mb)) and was found to harbor a germline
potentially pathogenic variant in POLD1 (c.1225C>T p.R409W).
Somatic mutation landscape of CRCs from biallelic MUTYH
pathogenic variant carriers. To evaluate the impact of biallelic
inactivation of MUTYH on the somatic mutational landscape, we
combined all 19 MUTYH positive tumors across the three datasets. We previously observed that SBS18 and SBS36 are associated
with speciﬁc pathogenic variants in MUTYH7. Speciﬁcally,
homozygous pathogenic variants at the 5′ end of the gene (exons
1–10) tend to give rise to SBS36, while SBS18 is more prevalent in
homozygous pathogenic variants at the 3′ end of the gene.
Comparing homozygous p.Y179C tumors to p.G396D homozygous tumors, SBS18 and SBS36 were both signiﬁcantly different
between these two groups of tumors (p = 0.015 and 0.024,
respectively, t-test; Supplementary Fig. 6). Three additional carriers with homozygotes near p.G396D (c.1214C>T p.P405L,
c.1227_1228dupGG p.E410Gfs*43 and c.1147del p.A385PfsTer23) support the possibility of domain-speciﬁc TMSs. When
aggregated with the p.G396D tumors, we see similarly signiﬁcant
differences between the TMSs (p = 0.011 and 0.012 respectively,
t-test; Supplementary Table 6).
Under the deﬁnition that hypermutated tumors have >10
mutations/Mb21, 12/19 (63.1%) MUTYH positives were considered hypermutated (mean ± SD 22.0 ± 8.8 somatic mutations).
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(a)

SBS18 + SBS36 (%)

SBS18/36 Distribution

Training set

(b)

Validation set

Test set

Reconstruction error (%)

Reconstruction error distribution

Training set

Validation set

Test set
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Somatic SNV count

(c)

Training set

Validation set
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Fig. 3 The distribution of SBS18/SBS36 tumor mutational signature, reconstruction error and somatic single nucleotide variant (SNV) count by the
ﬁve tumor classiﬁcation categories. Distribution of a SBS18/SBS36 tumor mutational signature, b tumor mutational signature reconstruction error, and
c adjusted somatic SNV count across 5649 CRCs in the training set, validation set, and test set, grouped by germline pathogenic variant status (tumor
classiﬁcations). The red horizontal line in each ﬁgure indicates the cut-offs that were determined based on the training set and validation set tumors. All
boxes correspond to the 25th and 75th percentiles and the whiskers represent 1.5× the inter-quartile range (IQR) extending from the boxes. Lines at the
middle of each box show the median. Individual observations are shown beyond the whiskers. Source data are provided as a Source Data ﬁle.

None showed evidence of MSI or somatic POLE exonuclease
domain mutations. In comparison, 469 (10.4%) of the 4510
microsatellite stable MUTYH negative tumors were considered
either hypermutated (n = 415) or ultra-hypermutated (n = 54)
(>100 mutations/Mb21), representing a signiﬁcant difference
(p = 4 × 10−8, binomial test) (Fig. 3c).
Somatic mutations were compared between the 19 MUTYH
positives and 5,352 MUTYH negatives (Fig. 5; expanded to include
MUTYH monoallelic tumors in Supplementary Fig. 7). Several
genes were found to have a signiﬁcant enrichment of nonsynonymous mutations in the MUTYH positives, including KRAS,
PIK3CA, and AMER1 (Table 2), consistent with previous ﬁndings16.
In KRAS and PIK3CA, a substantial proportion of all mutations

could be attributed to speciﬁc individual mutations: p.G12C (KRAS)
and p.Q546K (PIK3CA). We demonstrated the utility of these
hotspot mutations on smaller panels, showing that they identify
most biallelic carriers, though with lower sensitivity and speciﬁcity
than can be achieved using a larger panel that incorporates SBS18/
36 TMS (Supplementary Table 11). Both mutations were found to
be mutation types highly speciﬁc to the SBS18 and SBS36
mutational trinucleotide contexts, supporting a link to the DNA
damage proﬁle associated with biallelic MUTYH inactivation.
Similarly, the proportion of somatic mutations attributable to
SBS18/36, measured as relative likelihood22, was higher in all
enriched genes (Table 2), adding evidence that the association
between MUTYH positives and these genes has a mechanistic basis.
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Fig. 4 Distribution of SBS18/SBS36, somatic single nucleotide variants (SNVs), and tumor mutational signature (TMS) reconstruction error across
CRCs from training, validation, and test sets. a The CRCs from the biallelic MUTYH pathogenic variant carriers cluster together based on high SBS18/
SBS36 TMS and low TMS reconstruction error highlighting the need to include TMS reconstruction error in classiﬁer, and b CRCs with greater than 95%
likelihood of arising from biallelic MUTYH pathogenic variants based on TMS. The number of SNV mutations used in determining TMS (horizontal axis) and
the TMS reconstruction error (vertical axis) demonstrates the importance of low reconstruction error (<39%) and sufﬁcient somatic mutation count (≥9)
for correctly classifying tumors from biallelic MUTYH pathogenic variant carriers (true positives). Source data are provided as a Source Data ﬁle.

Discussion
We previously demonstrated that combining MUTYH-related
base excision repair deﬁciency mutational signatures SBS18 and
SBS36 was more effective than each signature alone for identifying germline biallelic MUTYH carriers using whole exome
sequencing of CRC tumors7. In this study, we trained, validated,
and then tested the effectiveness of our MUTYH SBS18/36 TMS
classiﬁer for identifying CRCs from biallelic MUTYH pathogenic
variant carriers in a large cohort of 5649 tumors that underwent
targeted multi-gene panel sequencing from formalin-ﬁxed parafﬁn-embedded (FFPE) tissue DNA. The addition of somatic
mutation count and TMS reconstruction error to the SBS18/36
threshold enabled the determination and validation of classiﬁer
parameters, namely SBS18/36 TMS proportion >51%, TMS
6

reconstruction error <39%, and somatic mutation count ≥9, that
yielded 100% accuracy for distinguishing MUTYH positives from
MUTYH negatives when applied to an independent dataset.
Furthermore, when the MUTYH TMS classiﬁer was applied to a
group of potential MUTYH biallelics as a functional approach to
evaluate the pathogenicity of VUSs, we found support for two
VUSs, p.G381W and c.577-5A>G, being likely pathogenic, while
for ﬁve VUSs, p.S304R, p.R274Q, p.R426C, p.R309C, and
p.T477T, our classiﬁer provided evidence they were likely benign.
Finally, we provided a detailed view of the somatic mutation
landscape of CRCs from biallelic MUTYH pathogenic variant
carriers based on a consensus set of 205 cancer genes, identifying
speciﬁc mutations in KRAS and PIK3CA genes that were associated with CRC tumorigenesis in biallelic MUTYH carriers.
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The characteristics of participants and each of the variants identiﬁed including ClinVar classiﬁcation, CADD and REVEL prediction scores, and gnomAD allele frequency, as well as the features of the optimized classiﬁer: SBS18 + SBS36 (>51% for positivity), TMS reconstruction
error (<39% for positivity), and somatic mutation count (≥9 for positivity) and the TMS-based pathogenicity prediction (positive for biallelic inactivation, negative for no biallelic inactivation). We indicate the seven VUSs that the classiﬁer provides evidence for reclassiﬁcation
as either likely pathogenic or likely benign. AgeDx age of diagnosis, PV pathogenic variant, TMS tumor mutational signature, VUS variant of uncertain signiﬁcance, (H) homozygous for germline variant; CADD score >20.0 or REVEL score >0.6 considered predicted pathogenic.
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Table 1 Participants categorized into the potential MUTYH biallelic group, based on either carrying a germline pathogenic variant and one or more VUSs, or multiple VUSs.
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Tumor sample ID

Fig. 5 Somatic mutation landscape of the 19 CRCs from biallelic MUTYH pathogenic variant carriers, as well as the 3 CRCs from carriers of variants of
uncertain clinical signiﬁcance that were reclassiﬁed as likely pathogenic in this study. The 40 most commonly mutated CRC genes48 are included, as
well as known CRC genes ALK, CSMD1, POLE, and POLD1. KRAS was found to be signiﬁcantly more commonly mutated in our biallelic MUTYH carrier CRCs.
Source data are provided as a Source Data ﬁle. AgeDx age of diagnosis, TMB tumor mutational burden (mutations/Mb), TMS tumor mutational signature.

Table 2 Signiﬁcantly enriched individual somatic mutations, as well as genes signiﬁcantly affected by non-synonymous somatic
mutations, observed in more than two MUTYH positive tumors.
Gene

Variant (context)

MUTYH positives

MUTYH negatives

p-value

SBS18/36 relative likelihood
(MUTYH positives vs
MUTYH negatives)

KRAS
PIK3CA
KRAS
AMER1
PIK3CA
ROBO2
TAF1L
SMAD4
SMAD2
APC
ERBB3

c.34G>T p.G12C (CCA>A)
c.1636C>A p.Q546K (GCA>A)
Gene-wide
Gene-wide
Gene-wide
Gene-wide
Gene-wide
Gene-wide
Gene-wide
Gene-wide
Gene-wide

16/19
7/19
17/19
9/19
10/19
3/19
5/19
6/19
4/19
17/19
4/19

127/5364
36/5364
2025/5364
592/5364
934/5364
55/5364
420/5364
638/5364
308/5364
3468/5364
388/5352

2 × 10−23
6 × 10−11
5 × 10−6
8 × 10−5
5 × 10−4
1 × 10−3
0.01
0.02
0.02
0.03
0.045

62%
83%
58% vs 17%
35% vs 12%
60% vs 12%
42% vs 20%
36% vs 13%
36% vs 13%
53% vs 13%
45% vs 18%
47% vs 13%

(84%)
(37%)
(89%)
(47%)
(53%)
(16%)
(26%)
(32%)
(21%)
(89%)
(21%)

(2.4%)
(0.7%)
(38%)
(11%)
(17%)
(1.0%)
(8%)
(12%)
(6%)
(65%)
(7%)

Somatic mutations observed in the signiﬁcantly enriched genes in MUTYH positives were more often associated with the trinucleotide contexts related to the SBS18/36 tumor mutational signatures
(TMS) as measured by the SBS18/36 relative likelihood. P-values were calculated with Fisher’s exact test (two-sided).

Effectiveness of TMSs to identify biallelic MUTYH carriers
from targeted panel sequencing data. We demonstrated that the
SBS18/36 TMS was robust when scaling down from a whole
exome capture (67 Mb)7 to a 1.34 Mb capture in the training set.
Furthermore, SBS18/36 remained highly correlated between the
different capture sizes of the validation (1.34 Mb, ρ = 0.904) and
test (1.96 Mb, ρ = 0.911) sets when compared with the whole
exome capture (Supplementary Table 12). This is important for
the generalizability and implementation of this MUTYH TMS
classiﬁer approach where tumor sequencing for clinical diagnostics is still largely embedded with targeted multi-gene panel
testing rather than whole exome or whole genome sequencing.
Developing and applying the classiﬁer parameters on different
capture sizes and assays (validation set = 1.34 Mb and test set =
8

1.96 Mb) while still achieving 100% accuracy supports the
potential for a broad application of this approach to different
clinical panels in use globally.
Resolving false positives in the TMS data. Despite demonstrating that the combined SBS18/36 TMS was effective at identifying CRCs from biallelic MUTYH carriers, the reduction in
capture size from exome to the 1.34 Mb targeted panel required
the inclusion of justiﬁable constraints in our classiﬁer to eliminate
false positives. By considering the number of observed somatic
variants and the TMS reconstruction error, all 24 false positives
observed in the independent dataset of 3022 CRCs were eliminated. Although the number of somatic mutations is a critical
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factor inﬂuencing the accuracy of reported TMSs, the literature
lacks consensus recommending minimum mutation counts, with
estimates ranging from 20023, 10024, 5025, down to 526. We showed
that the presence of either of the two hotspot mutations KRAS
p.G12C or PIK3CA p.Q546K resulted in 89.5% sensitivity (area
under the curve 0.932) for detecting MUTYH positive CRCs,
representing the lower limit of detection. For the 1.34 Mb capture,
we found that tumors with reconstruction error >39% or carrying
<9 somatic mutations were unlikely to generate a SBS18/36 TMS
proﬁle that was caused by biallelic inactivation of MUTYH. These
measures are negatively correlated (ρ = −0.41) and exclude tumors
for different reasons: the constraint on minimum somatic mutations reﬂects our previous ﬁnding that MUTYH positive CRCs
exhibit signiﬁcantly higher tumor mutational burden (TMB) than
MUTYH negative mismatch repair (MMR)-proﬁcient tumors7,
conﬁrmed by this larger study. The constraint on reconstruction
error eliminates tumors with TMSs that are not strongly supported
by the observed mutations. Increasing capture size tends to
increase both mutation count and reduce TMS reconstruction
error (Supplementary Tables 12 and 13) which will aid in reducing
false positives and the resolution of cases that fall close to the
current classiﬁer thresholds. Calibration of the MUTYH TMS
classiﬁer for custom captures that are unique to individual diagnostic laboratories may be required for effective implementation.
Application to variant classiﬁcation. We identiﬁed several key
ﬁndings that support the incorporation of our MUTYH TMS
classiﬁer in variant classiﬁcation approaches, mirroring the
multifactorial approach adopted when classifying MMR
variants:27,28 (1) Biallelic inactivation of MUTYH is necessary for
generation of the SBS18/36 TMS, providing functional evidence
of defective base excision repair, (2) the presence of the SBS18/36
TMS is a very strong predictor with 100% accuracy, (3) low false
positive rate when TMS reconstruction error and somatic
mutation count is added to the classiﬁer for targeted panel
sequencing data, and (4) somatic inactivation of MUTYH rarely
occurs as evidenced by the rarity of second somatic hits in
MUTYH monoallelics and no biallelic somatic inactivation was
observed in 5649 CRCs.
Based on these key observations, the MUTYH TMS classiﬁer
supported pathogenicity for two VUSs and an absence of support
for pathogenicity for ﬁve VUS. The MUTYH TMS classiﬁer
supported pathogenicity for at least one of c.933+3A>C and
c.1465G>A p.A489T variants, although further work is needed to
determine which one is or if they occur on a haplotype. Although
the presence of the SBS18/36 TMS provides strong evidence for
pathogenicity, the absence of the SBS18/36 TMS in supporting a
likely benign classiﬁcation should be considered with other
factors, namely, the possibility the VUS is on the same allele as
the pathogenic variant (in cis) and that we currently do not know
if there is variability in deleterious effects of different pathogenic
variants within MUTYH that result in a less dominant SBS18/36
TMS phenotype. Our ﬁndings support the application of the
MUTYH TMS classiﬁer as a tool to aid in variant classiﬁcation
approaches for MUTYH, and may help resolve some of the 58%
(689 of 1190) of variants in MUTYH in ClinVar that are classiﬁed
as either uncertain or with a conﬂicting classiﬁcation.
Somatic landscape and segregation of SBS18 and SBS36. Evidence is accumulating that the two signatures, SBS18 and SBS36,
segregate based on the MUTYH domain affected by the variant7:
the presence of the c.1187G>A p.G396D pathogenic variant
contributes predominantly to the SBS18 signature, while
c.536A>G p.Y179C contributes predominantly to SBS36.
Although SBS18 and SBS36 are similar signatures (cosine

ARTICLE

similarity 0.91) characterized by C>A transversions, they differ
substantially in speciﬁc contexts: GCA>A, CCA>A, and ACA>A.
This suggests that the affected domain alters tumor etiology,
which could help us better understand the biology of tumors that
arise and potentially inform clinical decision making. For
example, both signiﬁcantly enriched somatic mutations in KRAS
c.34G>T p.G12C (CCA>A) and PIK3CA c.1636C>A p.Q546K
(GCA>A) found in the MUTYH positives (Table 2) are in variant
contexts that differ signiﬁcantly between signatures, suggesting
domain-speciﬁc hotspots that may inform treatment decision
making.
The ﬁnding of commonly occurring speciﬁc somatic mutations
and mutated genes has treatment implications. Cross-referencing
the signiﬁcant biomarkers found in this study with existing
clinical actionability databases29 identiﬁed relevant drug associations, including FDA guidelines suggesting likely resistance to
Cetuximab and Panitumumab (KRAS p.G12C), and pre-clinical
trials suggesting responsiveness to MEK, ERK, BCL-XL, IGF-1R,
PI3K pathway inhibitors, and BH3 mimetics. Further, clinical
trials with direct inhibitors of the KRAS p.G12C allele30 are
ongoing in CRC and represent a promising potential therapy for
MUTYH positives. The FDA approval of the PD-1 inhibitor,
pembrolizumab, as a therapy for tumors with TMB greater than
1031 is also clinically relevant, with our results indicating that
most MUTYH positives are hypermutated (despite being MMRproﬁcient/microsatellite stable).
Limitations. We cannot exclude the possibility that other
mechanisms may cause SBS18/36 TMS that are more difﬁcult to
detect using panel sequenced data, such as LOH or structural
variants. We could not determine the impact tumor heterogeneity
might have on TMS. This might be more impactful for MUTYH
monoallelic carriers, where somatic inactivation of the wildtype
allele may occur later in tumorigenesis, however, overall we found
no signiﬁcant increase in the SBS18/36 TMS for MUTYH
monoallelic carrier CRCs compared with MUTYH negative CRCs
(10.8 ± 15.4% v. 7.1 ± 12.4%, p = 0.45, t-test) supporting previous
ﬁndings that monoallelic MUTYH pathogenic variants alone do
not result in loss of base excision repair7. Doublet and indel
signatures were not considered for this study due to low numbers
in panel-sequenced data. The majority of our MUTYH positives
carry the most common MUTYH pathogenic variants—by
expanding the analysis to different ethnic groups and a broader
diversity of MUTYH variants we can improve the generalizability
of the MUTYH TMS classiﬁer and potentially classify a greater
number of MUTYH variants. Similarly, the application to nonCRCs needs to be investigated with the aim of developing a tumor
agnostic MUTYH TMS classiﬁer.
In conclusion, identifying germline biallelic MUTYH carriers is
important for personalized surveillance and cancer prevention in
carriers and cancer risk prediction in relatives. The variable
clinical phenotype, lack of tumor-based screening to triage CRCaffected patients for MUTYH gene testing (akin to MMR
immunohistochemistry for Lynch syndrome), conﬂicting reports
regarding CRC risks in monoallelic MUTYH carriers, and the
absence of validated functional assays for variant classiﬁcation
present important clinical challenges that limit effective identiﬁcation and clinical management of MUTYH carriers. Key
ﬁndings from this study address these current limitations,
namely, the high accuracy of the tumor-based MUTYH TMS
classiﬁer for identifying biallelic MUTYH pathogenic variants and
the absence of SBS18/36 TMS in MUTYH monoallelics enabled
its application to variant classiﬁcation; we re-classiﬁed seven
germline VUSs, including supporting a likely pathogenic
classiﬁcation for two variants, c.1141G>T p.G381W and c.577-
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5A>G. The signiﬁcantly enriched somatic mutations in KRAS
c.34G>T p.G12C and PIK3CA c.1636C>A p.Q546K in MUTYH
positive CRCs, where both mutations correspond to dominant
contexts in SBS18/36, support a direct connection to MUTYHrelated base excision repair deﬁciency and provide potential
biomarkers for targeted therapy. With the increasing use of tumor
sequencing for precision oncology and clinical diagnostics, our
ﬁndings support the incorporation of our MUTYH TMS classiﬁer
into clinical tumor sequencing workﬂows as an accurate method
to identify biallelic MUTYH pathogenic variant carriers, particularly when biallelic MUTYH status is not suspected, or when
germline testing fails to yield a high-conﬁdence resolution due to
VUSs or conﬂicting results. Finally, the incorporation of analyses
directed towards TMS for identifying hereditary subtypes could
improve the detection of carriers and efforts to provide precision
prevention of CRC.
Methods
Study participants. All participants provided written informed consent, and each
study was approved by the relevant research ethics committee or institutional review
board. The University of Melbourne Human Research Ethics Committee approved
this research (study IDs 1750748, 1954921). Three independent sets of CRC-affected
individuals (Fig. 1) were included in the study: (1) a training set of 102 CRCs with
whole-exome sequencing from the Australasian Colon Cancer Family Registry
(ACCFR; n = 47)32,33 and the ANGELS study (n = 55)7; (2) a validation set of 2906
CRCs from GECCO sequenced at the Ontario Institute for Cancer Research with a
1.34 Mb targeted panel covering 205 genes;34 and (3) a test set of 3093 CRCs and
advanced adenomas from GECCO and sequenced at the Center for Inherited Disease
Research with a 1.96 Mb targeted panel covering 350 genes. DNA was extracted from
FFPE CRCs and matched with germline tissue (either blood-derived or normal
mucosa). A description of each of the studies and the breakdown of the CRCs are
provided in Supplementary Tables 2–5.
Tumor sequencing analysis. The mean coverage of MUTYH across the capture
regions for the training, validation, and test tumor datasets was 581.2 ± 156.9,
753.9 ± 578.0, and 1542.5 ± 1176.8, respectively (mean ± SD) (Supplementary
Fig. 8). For the training data, somatic variant calls were generated from the
intersection of Strelka v2.9.235 and Mutect236, with minimum tumor sequencing
depth of 25 reads and variant allele fraction of 10%. Variant calls were then limited
to the same 1.34 Mb capture region as the validation set. For the panel-sequenced
validation and test sets, somatic variants were generated from the intersection of
Strelka v1.0.1547 and Mutect, as per34 (see Supplementary Methods for more
detail). Tumors with at least one somatic single nucleotide variant (SNV) were
included for analysis, which comprised 102, 2528, and 3019 tumors in the training,
test, and validation sets, respectively, for a total of 5649 tumors assessed in this
study (Fig. 1).
LOH in the tumor across MUTYH was determined by identifying germline
heterozygous variants with homozygous somatic equivalents (see Supplementary
Methods)4. Copy number loss was assessed in PCAWG and TCGA CRC cohorts
with available consensus data37 and copy number segment data38, respectively (see
Supplementary Methods). TMB was calculated as the combined number of SNVs,
insertions, and deletions (indels) per megabase of capture sequence. MSI status was
determined using the method described by MSIseq39. Reported transcript and
protein changes in MUTYH refer to NM_001128425.1 and NP_001121897.1
respectively.
Germline MUTYH variant calling. The mean coverage of MUTYH across the
capture regions for the training, test, and validation germline datasets was
372.0 ± 118.1, 280.4 ± 352.6, and 425.7 ± 321.5 respectively (mean ± SD) (Supplementary Fig. 8). Germline variants in the test and validation datasets were called
using Strelka35 and limited to PASS calls with a minimum depth of 50 reads and a
minimum variant allele fraction of 10%.
Variant Classiﬁcations. Variants classiﬁed by ClinVar40 as likely pathogenic or
pathogenic were grouped and considered “pathogenic” for the purposes of this
study (n = 18 unique variants). Variants of uncertain signiﬁcance or with conﬂicting interpretations in ClinVar and/or variants that were predicted by computational metrics as pathogenic were retained and deﬁned as “potentially
pathogenic” variants (n = 105 unique variants) (Supplementary Fig. 1). The variant
classiﬁcation methods are detailed in the Supplementary Methods. The classiﬁed
variants were then used to classify all tumors into ﬁve categories (Fig. 1 and
Supplementary Table 1).
Tumor mutational signature (TMS) generation. TMSs were calculated for each
of the 5649 CRCs using the simulated annealing method described by
10

SignatureEstimation41, an approach previously applied successfully to panelsequenced data42. The pre-deﬁned set of Catalog of Somatic Mutations in Cancer
(COSMIC) mutational signatures v3.143 was reduced to a set of 14 signatures
previously observed in 59 whole-genome sequenced CRCs as determined in
PCAWG1, including the known base excision repair signatures SBS18 and SBS36
associated with defective MUTYH16 and SBS30 associated with defective
NTHL16,44. The TMS reconstruction error measures how accurately a reported
signature proﬁle reﬂects the observed mutations and was calculated as the cosine
distance between the observed mutational context counts and the predicted
mutational context counts computed from the mutational signatures45. We used
the Python (v3.7.4) SciPy (v1.4.1)46 implementation of simulated annealing
(“basinhopping”) to calculate the linear combination of TMSs that minimized
reconstruction error.
Determining SBS18/36 TMS thresholds for identifying MUTYH positive
CRCs. From the training set, 8 CRCs from known MUTYH positives and 92
conﬁrmed MUTYH negatives were used to establish a combined SBS18 and SBS36
TMS threshold for identifying CRCs from biallelic MUTYH carriers that were
speciﬁc to the targeted 1.34 Mb/205 gene panel (as previously applied to whole
exome sequencing data7).
Predicting biallelic MUTYH carriers from the validation and test sets of CRCs
and evaluating the accuracy of TMSs. Based on the combined SBS18/36 TMS
threshold calculated from the training set of 100 CRCs, we predicted the MUTYH
status of the validation set of CRCs and assessed its accuracy against the tumor
classiﬁcations based on variant calling. The TMS-based classiﬁer was then optimized using the validation set, by considering the number of somatic mutations
and the TMS reconstruction error in addition to the SBS18/36 TMS threshold. The
test set was then utilized as an independent dataset to assess the accuracy of the
optimized classiﬁer. The test set somatic mutation count was compared to the
classiﬁer threshold after adjusting by the proportional difference in panel sizes
(1.34/1.96). To further assess the classiﬁer’s utility for MUTYH variant classiﬁcation, we applied it to CRCs deﬁned as MUTYH monoallelics, potential MUTYH
biallelics, and MUTYH uncertain (Fig. 1).
Statistical analyses. All statistical analyses were performed using Python 3.7.4.
NumPy 1.17.347 was used for numerical calculations. Statistical calculations were
performed using SciPy 1.4.146. All t-tests were performed as two-sided and
assuming equal variance with all p-values reported unadjusted unless otherwise
speciﬁed.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
All data generated in this study are included in this published article (and its
supplementary information ﬁles/Source Data ﬁle). The original panel-sequenced data
used in this study are available at the database of Genotypes and Phenotypes (dbGaP).
The Ontario Institute of Cancer Research (OICR) data is available under accession code
phs002050.v1.p1. The Center for Inherited Disease Research (CIDR) data is available
under accession code phs001905.v1.p1. The whole exome sequencing data used in this
study has been previously published7. This data is available from the Colon Cancer
Family Registry via a “request to collaborate with the CCFR” application process (www.
coloncfr.org/collaboration). Colorectal Adenocarcinoma TCGA copy number data was
downloaded from cBioPortal (https://www.cbioportal.org/) using the data sequenced in
the Colorectal Adenocarcinoma (TCGA, PanCancer Atlas) study. Copy number loss was
assessed in the PCAWG with the consensus copy number data downloaded from https://
dcc.icgc.org/releases/PCAWG/consensus_cnv. Mutational signature deﬁnitions were
downloaded from the COSMIC website at https://cancer.sanger.ac.uk/signatures/
downloads/. Source data are provided with this paper.
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